Close Menu

NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx has received CE marking for an assay to detect resistant strains of Mycoplasma genitalium, the company announced today.

The ResistancePlus MG assay detects M. genitalium as well as mutations in the bacterium's 23S rRNA that confer resistance to the macrolide drug azithromycin.

"As with the better known STD, gonorrhea, M. genitalium has developed serious treatment challenges because of the recent rise of antibiotic resistance," Colin Denver, SpeeDx's CEO, noted in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.